Household & Personal Products · Founded 1975 · www.dabur.com · BSE 500096 · NSE DABUR (I) · ISIN INE016A01026
No Notes Added Yet
Business
Dabur India Ltd. is one of India's leading Fast Moving Consumer Goods (FMCG) companies. Its core business involves manufacturing, marketing, and selling a diverse portfolio of consumer products across various categories. The company is particularly known for its Ayurvedic and natural healthcare products, alongside personal care and food & beverage offerings. Dabur makes money by selling these products to consumers through an extensive distribution network in India and over 120 countries globally, leveraging strong brand equity and a focus on natural ingredients.
Revenue Mix
Dabur's business is broadly diversified across three main categories:
Consumer Care Business: This includes Home Care (air fresheners, mosquito repellents), Personal Care (hair care, oral care, skin care), and Health Care (Ayurvedic medicines, health supplements like Chyawanprash, honey).
Food & Beverages: Comprising fruit juices (Real brand), packaged foods, and beverages.
International Business: Sales generated from markets outside India, primarily in MENA, SAARC, Africa, and other regions.
The company does not publicly disclose precise revenue percentages for each sub-segment within these broader categories on a frequent basis, but Consumer Care and Food & Beverages contribute the bulk of its domestic revenues.
Industry
Dabur operates in the highly competitive Indian FMCG industry, which is characterized by intense competition from multinational corporations (e.g., Hindustan Unilever, Procter & Gamble), large domestic players (e.g., Marico, Godrej Consumer Products, ITC), and a multitude of regional and unorganized players. The industry thrives on extensive distribution, brand loyalty, and effective marketing. Dabur holds a strong and unique position due to its deep-rooted Ayurvedic heritage and natural product portfolio, making it a leader in several categories like health supplements, fruit juices, and specific oral care segments. Its established brands and rural penetration are key strengths in this market.
MOAT
Brand Equity and Trust: Dabur possesses a portfolio of highly recognized and trusted brands (e.g., Dabur Chyawanprash, Vatika, Real, Dabur Red Toothpaste). Its long history and association with Ayurveda have built significant consumer trust.
Ayurvedic/Natural Expertise: A unique competitive edge derived from over a century of expertise in Ayurvedic formulations and natural product development, catering to the growing consumer preference for natural solutions.
Extensive Distribution Network: A deep and wide distribution reach, especially in rural and semi-urban India, which is critical for FMCG success in a geographically diverse market.
Scale of Operations: Large-scale manufacturing, marketing, and R&D capabilities provide cost efficiencies and support new product development.
Growth Drivers
Health & Wellness Trend: Increasing consumer awareness and preference for natural, herbal, and Ayurvedic products aligns directly with Dabur's core offerings.
Premiumization: Shifting consumers towards higher-value, specialized products within existing categories, offering scope for value growth.
Rural Market Penetration: Under-penetrated rural markets in India represent a significant growth opportunity as disposable incomes rise and distribution improves.
E-commerce & Digital Channels: Expanding presence and sales through online platforms and direct-to-consumer models.
New Product Development & Innovation: Continuous innovation and introduction of new products or variants to capture evolving consumer tastes and market share.
International Expansion: Growth in key overseas markets, particularly in regions with a growing diaspora or affinity for natural products.
Risks
Intense Competition: Fierce competition from established national and international players, as well as smaller regional players, can lead to pricing pressures and market share erosion.
Raw Material Price Volatility: Dependence on agricultural commodities and other raw materials makes the company susceptible to price fluctuations, impacting margins.
Regulatory Changes: Changes in food safety standards, advertising regulations, or other health-related policies could impact product formulations, marketing, and operational costs.
Economic Slowdown: A downturn in economic growth and reduced consumer spending, particularly in discretionary categories, can adversely affect sales volumes and revenue.
Supply Chain Disruptions: Global or regional events (e.g., pandemics, geopolitical conflicts) can disrupt manufacturing, logistics, and raw material availability.
Management & Ownership
Dabur India Ltd. is promoted by the Burman family, who are the founders and maintain a significant ownership stake. The company operates with a blend of family members in strategic roles and a professional management team, which includes experienced executives from various functional backgrounds. The ownership structure includes a substantial promoter holding alongside significant stakes held by domestic and foreign institutional investors, and public shareholders, reflecting a well-diversified investor base.
Outlook
Dabur is strategically positioned to capitalize on India's long-term FMCG consumption growth, driven by increasing disposable incomes, a young population, and growing preference for health and natural products. Its strong Ayurvedic heritage, extensive distribution network, and diversified product portfolio provide a solid foundation. The company's focus on innovation and digital channels can further enhance its market reach and relevance. However, Dabur operates in a highly competitive market where sustained growth requires continuous brand investment, efficient cost management to counter raw material inflation, and effective new product development. The ability to navigate macroeconomic uncertainties and maintain agility in a dynamic consumer landscape will be key to its continued success.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3255 | 2815 | 3349 | 3029 | 3355 | 2830 | 3405 | 3191 | 3559 | 3038 |
| Other Income | 127 | 129 | 129 | 152 | 128 | 141 | 144 | 140 | 141 | 175 |
| Total Income | 3382 | 2943 | 3479 | 3180 | 3483 | 2971 | 3549 | 3331 | 3699 | 3213 |
| Total Expenditure | 2587 | 2348 | 2694 | 2476 | 2673 | 2403 | 2737 | 2603 | 2825 | 2576 |
| Operating Profit | 795 | 596 | 784 | 704 | 810 | 568 | 812 | 728 | 875 | 637 |
| Interest | 36 | 35 | 33 | 47 | 44 | 39 | 35 | 40 | 31 | 40 |
| Depreciation | 97 | 107 | 109 | 111 | 109 | 117 | 114 | 115 | 117 | 122 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -15 | 0 |
| Profit Before Tax | 662 | 453 | 643 | 546 | 657 | 412 | 663 | 573 | 711 | 475 |
| Provision for Tax | 155 | 111 | 148 | 128 | 142 | 99 | 154 | 128 | 158 | 112 |
| Profit After Tax | 507 | 342 | 495 | 417 | 515 | 313 | 509 | 445 | 554 | 363 |
| Adjustments | 7 | 8 | 6 | 8 | 7 | 7 | 5 | 8 | 6 | 6 |
| Profit After Adjustments | 514 | 350 | 500 | 425 | 522 | 320 | 514 | 453 | 560 | 369 |
| Adjusted Earnings Per Share | 2.9 | 2 | 2.8 | 2.4 | 2.9 | 1.8 | 2.9 | 2.6 | 3.2 | 2.1 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 7827 | 7780 | 7614 | 7722 | 8515 | 8685 | 9562 | 10889 | 11530 | 12404 | 12563 | 13193 |
| Other Income | 158 | 217 | 303 | 305 | 296 | 305 | 325 | 393 | 445 | 482 | 550 | 600 |
| Total Income | 7985 | 7997 | 7917 | 8027 | 8811 | 8990 | 9887 | 11282 | 11975 | 12886 | 13113 | 13792 |
| Total Expenditure | 6511 | 6261 | 6106 | 6107 | 6778 | 6895 | 7562 | 8638 | 9370 | 10008 | 10251 | 10741 |
| Operating Profit | 1474 | 1735 | 1810 | 1920 | 2033 | 2095 | 2325 | 2644 | 2605 | 2878 | 2862 | 3052 |
| Interest | 40 | 48 | 59 | 53 | 60 | 50 | 31 | 39 | 78 | 124 | 164 | 146 |
| Depreciation | 115 | 133 | 141 | 160 | 174 | 217 | 237 | 250 | 307 | 395 | 441 | 468 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -15 | -75 | -100 | 0 | -85 | 0 | 0 | 0 | -15 |
| Profit Before Tax | 1319 | 1554 | 1611 | 1693 | 1725 | 1728 | 2056 | 2269 | 2219 | 2359 | 2258 | 2422 |
| Provision for Tax | 251 | 300 | 330 | 335 | 279 | 280 | 361 | 526 | 517 | 547 | 517 | 552 |
| Profit After Tax | 1068 | 1254 | 1280 | 1358 | 1446 | 1448 | 1695 | 1742 | 1701 | 1811 | 1740 | 1871 |
| Adjustments | -3 | -3 | -3 | -3 | -4 | -3 | -2 | -3 | 6 | 31 | 27 | 25 |
| Profit After Adjustments | 1066 | 1251 | 1277 | 1354 | 1442 | 1445 | 1693 | 1739 | 1707 | 1843 | 1768 | 1896 |
| Adjusted Earnings Per Share | 6.1 | 7.1 | 7.2 | 7.7 | 8.2 | 8.2 | 9.6 | 9.8 | 9.6 | 10.4 | 10 | 10.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 1% | 5% | 8% | 5% |
| Operating Profit CAGR | -1% | 3% | 6% | 7% |
| PAT CAGR | -4% | -0% | 4% | 5% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -13% | -8% | -5% | 3% |
| ROE Average | 17% | 19% | 20% | 25% |
| ROCE Average | 21% | 23% | 25% | 28% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 3354 | 4171 | 4847 | 5707 | 5632 | 6606 | 7664 | 8381 | 8973 | 9866 | 10801 |
| Minority's Interest | 18 | 22 | 25 | 27 | 31 | 36 | 37 | 41 | 468 | 437 | 410 |
| Borrowings | 211 | 342 | 470 | 364 | 26 | 163 | 1 | 250 | 299 | 536 | 304 |
| Other Non-Current Liabilities | 378 | 411 | 165 | 170 | 87 | 63 | 193 | 289 | 303 | 347 | 397 |
| Total Current Liabilities | 2883 | 2877 | 2225 | 2434 | 2660 | 2464 | 2934 | 3323 | 3609 | 3930 | 4318 |
| Total Liabilities | 6844 | 7823 | 7732 | 8702 | 8437 | 9332 | 10829 | 12284 | 13652 | 15116 | 16230 |
| Fixed Assets | 1877 | 1667 | 1903 | 1974 | 1917 | 2201 | 2192 | 2259 | 3532 | 3770 | 3946 |
| Other Non-Current Assets | 1771 | 2316 | 2714 | 3288 | 2933 | 2251 | 3861 | 5708 | 5872 | 5667 | 5751 |
| Total Current Assets | 3195 | 3839 | 3114 | 3438 | 3586 | 4880 | 4776 | 4317 | 4249 | 5680 | 6532 |
| Total Assets | 6844 | 7823 | 7732 | 8702 | 8437 | 9332 | 10829 | 12284 | 13652 | 15116 | 16230 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 313 | -47 | 35 | 116 | 89 | 38 | 92 | 189 | 227 | 98 | -21 |
| Cash Flow from Operating Activities | 1047 | 1187 | 1227 | 1092 | 1499 | 1614 | 2115 | 1802 | 1488 | 2013 | 1987 |
| Cash Flow from Investing Activities | -876 | -730 | -807 | -540 | 337 | -517 | -1406 | -1275 | -587 | -972 | -449 |
| Cash Flow from Financing Activities | -417 | -374 | -339 | -577 | -1888 | -1043 | -613 | -490 | -1035 | -1161 | -1405 |
| Net Cash Inflow / Outflow | -246 | 82 | 81 | -26 | -52 | 54 | 95 | 36 | -133 | -119 | 132 |
| Closing Cash & Cash Equivalent | 68 | 35 | 116 | 89 | 38 | 92 | 189 | 227 | 98 | -21 | 112 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 6.07 | 7.11 | 7.25 | 7.69 | 8.17 | 8.18 | 9.58 | 9.84 | 9.64 | 10.4 | 9.97 |
| CEPS(Rs) | 6.74 | 7.89 | 8.07 | 8.61 | 9.17 | 9.42 | 10.93 | 11.27 | 11.33 | 12.45 | 12.31 |
| DPS(Rs) | 2 | 2.25 | 2.25 | 7.5 | 2.75 | 3 | 4.75 | 5.2 | 5.2 | 5.5 | 8 |
| Book NAV/Share(Rs) | 18.8 | 23.19 | 27.01 | 31.87 | 31.46 | 36.85 | 42.66 | 46.57 | 50.31 | 55.14 | 60.4 |
| Core EBITDA Margin(%) | 16.65 | 19.3 | 19.57 | 19.13 | 18.57 | 18.5 | 18.87 | 18.55 | 16.65 | 17.09 | 15.92 |
| EBIT Margin(%) | 17.19 | 20.36 | 21.68 | 20.68 | 19.08 | 18.37 | 19.69 | 19.02 | 17.71 | 17.71 | 16.67 |
| Pre Tax Margin(%) | 16.69 | 19.75 | 20.91 | 20.05 | 18.45 | 17.86 | 19.4 | 18.7 | 17.11 | 16.83 | 15.54 |
| PAT Margin (%) | 13.51 | 15.94 | 16.62 | 16.08 | 15.47 | 14.97 | 16 | 14.36 | 13.12 | 12.92 | 11.98 |
| Cash Profit Margin (%) | 14.97 | 17.63 | 18.46 | 17.97 | 17.33 | 17.21 | 18.23 | 16.42 | 15.48 | 15.74 | 15.02 |
| ROA(%) | 16.72 | 17.1 | 16.46 | 16.52 | 16.88 | 16.3 | 16.81 | 15.08 | 13.12 | 12.59 | 11.1 |
| ROE(%) | 36.36 | 33.97 | 28.97 | 26.18 | 25.89 | 23.99 | 24.12 | 22.09 | 19.84 | 19.39 | 17 |
| ROCE(%) | 34.29 | 34.49 | 30.92 | 28.01 | 27.51 | 26.41 | 27.56 | 26.73 | 23.9 | 23.65 | 21.47 |
| Receivable days | 32 | 35.25 | 34.59 | 29.32 | 30.05 | 31.08 | 23.69 | 18.17 | 21.03 | 22.75 | 22.46 |
| Inventory Days | 44.91 | 48 | 52.21 | 51.07 | 49.9 | 50.56 | 53.63 | 54.84 | 55.37 | 51.7 | 53.36 |
| Payable days | 135.92 | 147.39 | 172.56 | 183.32 | 169.86 | 174.51 | 174.4 | 173.94 | 164.33 | 176.6 | 200.11 |
| PER(x) | 43.75 | 35.03 | 38.23 | 42.53 | 50.09 | 55.06 | 56.44 | 54.54 | 56.57 | 50.31 | 50.79 |
| Price/Book(x) | 14.12 | 10.74 | 10.26 | 10.26 | 13 | 12.22 | 12.67 | 11.52 | 10.83 | 9.49 | 8.39 |
| Dividend Yield(%) | 0.75 | 0.9 | 0.81 | 2.29 | 0.67 | 0.67 | 0.88 | 0.97 | 0.95 | 1.05 | 1.58 |
| EV/Net Sales(x) | 6.04 | 5.71 | 6.5 | 7.54 | 8.53 | 9.13 | 9.89 | 8.74 | 8.43 | 7.51 | 7.16 |
| EV/Core EBITDA(x) | 32.09 | 25.59 | 27.34 | 30.33 | 35.72 | 37.85 | 40.69 | 35.99 | 37.33 | 32.38 | 31.42 |
| Net Sales Growth(%) | 10.63 | -0.61 | -2.13 | 1.42 | 10.27 | 1.99 | 10.1 | 13.88 | 5.89 | 7.58 | 1.28 |
| EBIT Growth(%) | 14.27 | 17.86 | 4.21 | 4.58 | 2.19 | -0.41 | 17.42 | 10.56 | -0.45 | 8.1 | -2.48 |
| PAT Growth(%) | 16.59 | 17.35 | 2.11 | 6.05 | 6.52 | 0.12 | 17.06 | 2.79 | -2.35 | 6.46 | -3.91 |
| EPS Growth(%) | 15.78 | 17.21 | 1.92 | 6.06 | 6.2 | 0.14 | 17.17 | 2.68 | -2.06 | 7.93 | -4.09 |
| Debt/Equity(x) | 0.29 | 0.2 | 0.2 | 0.17 | 0.13 | 0.08 | 0.05 | 0.11 | 0.11 | 0.12 | 0.07 |
| Current Ratio(x) | 1.11 | 1.33 | 1.4 | 1.41 | 1.35 | 1.98 | 1.63 | 1.3 | 1.18 | 1.45 | 1.51 |
| Quick Ratio(x) | 0.77 | 0.95 | 0.9 | 0.9 | 0.86 | 1.42 | 1.04 | 0.72 | 0.62 | 0.95 | 0.98 |
| Interest Cover(x) | 33.89 | 33.05 | 28.29 | 32.91 | 29.95 | 35.87 | 67.73 | 59.77 | 29.36 | 19.99 | 14.81 |
| Total Debt/Mcap(x) | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0 | 0.01 | 0.01 | 0.01 | 0.01 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.24 | 66.25 | 66.24 | 66.25 | 66.26 | 66.27 | 66.22 | 66.22 | 66.23 | 66.25 |
| FII | 16.49 | 15.83 | 14.98 | 15.04 | 13.27 | 12.68 | 11.84 | 10.89 | 10.05 | 9.98 |
| DII | 11.72 | 12.52 | 13.52 | 13.63 | 14.88 | 15.68 | 16.23 | 17.39 | 18.38 | 18.56 |
| Public | 5.54 | 5.4 | 5.26 | 5.08 | 5.58 | 5.37 | 5.7 | 5.5 | 5.34 | 5.22 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 117.39 | 117.4 | 117.4 | 117.41 | 117.44 | 117.45 | 117.45 | 117.45 | 117.47 | 117.5 |
| FII | 29.22 | 28.04 | 26.55 | 26.66 | 23.52 | 22.47 | 21.01 | 19.31 | 17.83 | 17.69 |
| DII | 20.77 | 22.18 | 23.96 | 24.15 | 26.38 | 27.8 | 28.79 | 30.85 | 32.6 | 32.91 |
| Public | 9.82 | 9.58 | 9.32 | 9 | 9.89 | 9.51 | 10.12 | 9.76 | 9.48 | 9.26 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 177.2 | 177.2 | 177.23 | 177.23 | 177.23 | 177.23 | 177.37 | 177.37 | 177.37 | 177.37 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +1% | +5% | +8% | +5% |
| Operating Profit CAGR | -1% | +3% | +6% | +7% |
| PAT CAGR | -4% | 0% | +4% | +5% |
| Share Price CAGR | -13% | -8% | -5% | +3% |
| ROE Average | +17% | +19% | +20% | +25% |
| ROCE Average | +21% | +23% | +25% | +28% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.24 | 66.25 | 66.24 | 66.25 | 66.26 | 66.27 | 66.22 | 66.22 | 66.23 | 66.25 |
| FII | 16.49 | 15.83 | 14.98 | 15.04 | 13.27 | 12.68 | 11.84 | 10.89 | 10.05 | 9.98 |
| DII | 11.72 | 12.52 | 13.52 | 13.63 | 14.88 | 15.68 | 16.23 | 17.39 | 18.38 | 18.56 |
| Public | 33.76 | 33.75 | 33.76 | 33.75 | 33.74 | 33.73 | 33.78 | 33.78 | 33.77 | 33.75 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 117.39 | 117.4 | 117.4 | 117.41 | 117.44 | 117.45 | 117.45 | 117.45 | 117.47 | 117.5 |
| FII | 29.22 | 28.04 | 26.55 | 26.66 | 23.52 | 22.47 | 21.01 | 19.31 | 17.83 | 17.69 |
| DII | 20.77 | 22.18 | 23.96 | 24.15 | 26.38 | 27.8 | 28.79 | 30.85 | 32.6 | 32.91 |
| Public | 59.82 | 59.8 | 59.83 | 59.82 | 59.79 | 59.78 | 59.92 | 59.92 | 59.9 | 59.87 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 177.2 | 177.2 | 177.23 | 177.23 | 177.23 | 177.23 | 177.37 | 177.37 | 177.37 | 177.37 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.